-+ 0.00%
-+ 0.00%
-+ 0.00%
Zealand Pharma says survodutide meets cardiovascular safety endpoint in Phase 3 trial
Share
Listen to the news
Zealand Pharma says survodutide meets cardiovascular safety endpoint in Phase 3 trial
  • Zealand Pharma announced Boehringer Ingelheim’s survodutide met the primary cardiovascular safety endpoint in the Phase 3 SYNCHRONIZE-CVOT trial.
  • Survodutide did not increase major cardiovascular event risk versus placebo in adults with overweight or obesity at elevated cardiovascular risk.
  • Treatment improved blood pressure, waist circumference and body weight, though gastrointestinal side effects led some participants to discontinue.
  • Results were presented today at the American Heart Association Scientific Sessions and published simultaneously in The Lancet.
  • The findings complete the registrational Phase 3 obesity program, supporting Boehringer Ingelheim’s move toward global regulatory submissions.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zealand Pharma A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611090945OMX_____CNEWS_EN_GNW1001302639_en) on November 09, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending